<DOC>
	<DOCNO>NCT02789878</DOCNO>
	<brief_summary>This randomize study evaluate efficacy safety neoadjuvant androgen deprivation therapy goserelin abiraterone without apalutamide prior radical prostatectomy patient diagnose localized high-risk prostate cancer .</brief_summary>
	<brief_title>Neoadjuvant Androgen Deprivation Therapy Plus Abiraterone With Without Apalutamide High-Risk Prostate Cancer</brief_title>
	<detailed_description>In prostate specific antigen ( PSA ) era , 15 % 20 % patient diagnose high-risk localized disease radical prostatectomy standard therapy subgroup patient . However , despite best local therapy , 30-60 % high-risk patient eventually develop biochemical relapse significant proportion patient may progress metastatic disease die prostate cancer . Currently , data support use neoadjuvant therapy patient high-risk disease since study fail demonstrate clinically significant benefit standard androgen deprivation therapy ( ADT ) . Following improved outcome malignancy use neoadjuvant therapy active drug metastatic setting , grow interest evaluate new-generation androgen receptor ( AR ) -targeted therapy earlier stage prostate cancer . Therefore , goal study evaluate efficacy safety neoadjuvant therapy ADT abiraterone versus maximal androgen blockade use ADT , abiraterone apalutamide patient high-risk localized prostate cancer .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Histologic confirm prostatic adenocarcinoma Noncastrate level testosterone ( &gt; 150 ng/dL ) Highrisk localize prostate cancer , define either : Tumor stage T3 digital rectal examination , Primary tumor Gleason score ≥ 8 , PSA ≥ 20 ng/mL Willing undergo prostatectomy primary treatment localized prostate cancer Adequate hematologic , renal hepatic function : WBC &gt; 3000/uL Platelets &gt; 150,000/uL Creatinine &lt; 2 mg/dL Bilirubin &lt; 1.5 x upper limit normal ( ULN ) AST/ALT &lt; 2 x ULN Karnofsky Performance Status ( KPS ) ≥ 80 % Able swallow study drug whole tablet Pathological find consistent small cell , ductal neuroendocrine carcinoma prostate Current prior hormonal therapy , radiation therapy chemotherapy prostate cancer Evidence metastatic disease ( M1 ) image study Other prior malignancy less equal 5 year prior randomization exception squamous basal cell skin carcinoma Abnormal cardiac function manifest NYHA ( New York Heart Association ) class III IV heart failure History prior cardiac arrhythmia . Evidence serious and/or unstable preexist medical , psychiatric condition ( include laboratory abnormality ) could interfere patient safety provision inform consent participate study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Neoadjuvant therapy</keyword>
	<keyword>High-risk Prostate Cancer</keyword>
</DOC>